Humanigen, Inc
HGENDelisted Oct 12, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001293310
Humanigen, Inc was delisted on Oct 12, 2023; its insiders filed their last Form 4 on Oct 20, 2023; 38 institutions reported holding it in 13F filings for Q2 2023, worth $839.7K in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:44 PM ET
Revenue flow, FY2022
Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2022: $70.7M (2813.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 28, 2022 | – | – | – |
| Revenue | $2.51M | $3.60M | $312.0K | – | – |
| Operating expenses | $70.8M | $236.4M | $88.5M | $8.94M | $11.3M |
| Research and development | $55.2M | $213.1M | $72.7M | $2.62M | $2.22M |
| Selling, general and administrative | $15.6M | $23.3M | $15.8M | $6.33M | $9.11M |
| Operating income | -$68.3M | -$232.8M | -$88.2M | -$8.94M | -$11.3M |
| Interest expense | $2.92M | $2.26M | $1.34M | $1.35M | $852.0K |
| Income tax | – | $21.6M | – | – | – |
| Net income | -$70.7M | -$236.6M | -$89.5M | -$10.3M | -$12.0M |
| EPS, basic | $-0.79 | – | – | – | – |
| EPS, diluted | $-0.79 | – | – | – | – |
| Weighted shares, basic | 89.2M | – | – | – | – |
| Weighted shares, diluted | 89.2M | – | – | – | – |
| Margins and growth | |||||
| Operating margin | -2716.9% | -6474.9% | -28268.6% | – | – |
| Net margin | -2813.4% | -6582.7% | -28697.1% | – | – |
| Revenue growth, year over year | −30.1% | +1,052.2% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 28, 2022 | – | – | – |
| Cash and equivalents | $10.2M | $70.0M | $67.7M | $143.0K | $814.0K |
| Total current assets | $11.1M | $71.0M | $68.2M | $452.0K | $1.30M |
| Total assets | $11.2M | $71.1M | $68.3M | $523.0K | $1.37M |
| Accounts payable | $40.5M | $44.7M | $13.1M | $5.05M | $2.86M |
| Total current liabilities | $56.2M | $68.7M | $20.4M | $13.6M | $8.26M |
| Long-term debt | – | $25.0M | – | $6.49M | – |
| Total liabilities | $58.0M | $94.7M | $22.8M | $14.8M | $9.48M |
| Shareholders' equity | -$46.8M | -$23.7M | $45.5M | -$14.3M | -$8.11M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 28, 2022 | – | – | – |
| Operating cash flow | -$76.7M | -$184.0M | -$69.9M | -$4.00M | -$6.21M |
| Depreciation and amortization | – | – | – | – | $19.0K |
| Stock-based compensation | $5.81M | $5.37M | $2.11M | $2.02M | $4.81M |
| Investing cash flow | – | – | -$20.0K | – | – |
| Financing cash flow | $16.8M | $186.3M | $137.5M | $3.33M | $6.26M |
| Net change in cash | – | $2.28M | $67.6M | -$671.0K | $47.0K |
| Ratio | |||||
| Stock-based compensation, % of revenue | 231.1% | 149.3% | 676.3% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 3, 2023 | 119.1M | +68.6% | SEC |
| Mar 16, 2023 | 119.1M | +82.3% | SEC |
| Nov 9, 2022 | 119.1M | +86.6% | SEC |
| Aug 9, 2022 | 103.7M | +74.5% | SEC |
| May 2, 2022 | 70.6M | +19.5% | SEC |
| Feb 16, 2022 | 65.3M | +22.2% | SEC |
| Nov 9, 2021 | 63.8M | +23.6% | SEC |
| Aug 5, 2021 | 59.4M | −71.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.